Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?

被引:99
|
作者
Mawdsley, S [1 ]
Glynne-Jones, R
Grainger, J
Richman, P
Makris, A
Harrison, M
Ashford, R
Harrison, RA
Osborne, M
Livingstone, JI
Meyrick-Thomas, J
Northover, JMA
Windsor, A
Novell, R
Wallace, M
机构
[1] Mt Vernon Canc Ctr, Northwood HA6 2RN, Middx, England
[2] Barnet Gen Hosp, Barnet, England
[3] Watford Dist Gen Hosp, Watford, England
[4] Northwick Pk Hosp & Clin Res Ctr, Harrow HA1 3UJ, Middx, England
[5] Luton & Dunstable Gen Hosp, Luton, Beds, England
关键词
preoperative chemoradiotherapy; rectal adenocarcinoma; tumor downstaging; circumferential resection margin; prognostic factors;
D O I
10.1016/j.ijrobp.2005.03.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This study set out to determine the impact of a positive circumferential resection margin (CRM) (R1-R2) and pathologic downstaging on local recurrence and survival in patients with borderline resectable or unresectable rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy (CRT). Methods and Materials: A total of 150 patients with locally advanced rectal cancer were treated with long-course neoadjuvwnt CRT-using low-dose folinic acid and 5-fluorouracil. CRT was followed 6-12 weeks later by surgical excision. The CRM rate and incidence, site, and pattern of local and systemic recurrences were recorded. The median follow-up was 25 months. Results: The overall median survival was 37 months, with a 5-year overall survival rate of 34%. Of the 150 patients, 122 -underwent curative resection; 12% had a complete pathologic response, and downstaging to pT1-T2 occurred in an additional 16%. A negative CRM (R0) was achieved in 65% overall (98 of 150). Local recurrence occurred in 10% of those with R0 resection and 62% of those with R1-R2 resections. Distant metastases occurred in 29% of those with R0 resections and 75% of those with R1-R2 resections. The 3-year disease-free and 3-year overall survival rate was 9% and 25% and 52% and 64%, respectively, for patients with and without a histologically positive CRM. Conclusion: After 5-fluorouracil- based CRT, a positive CRM predicted for a high risk of subsequent local r-ecurrence and a 3-year disease-free survival rate of only 9%. For this reason, the CRM should be considered a major prognostic factor and should be validated in future trials as an early alternative clinical endpoint. (c) 2005 Elsevier Inc.
引用
收藏
页码:745 / 752
页数:8
相关论文
共 50 条
  • [31] Can pathological complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for T3–T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision?
    R. Hughes
    R. Glynne-Jones
    J. Grainger
    P. Richman
    A. Makris
    M. Harrison
    R. Ashford
    R. A. Harrison
    J. I. Livingstone
    P. J. McDonald
    J. Meyrick Thomas
    I. C. Mitchell
    J. M. A. Northover
    R. Phillips
    M. Wallace
    A. Windsor
    J. R. Novell
    International Journal of Colorectal Disease, 2006, 21 : 11 - 17
  • [32] Hepatocellular Carcinoma with Gastric Metastasis Mimicking a 4 cm Gastrointestinal Stromal Tumor After a 3-year Disease-free Interval
    Chen, Wei -Ting
    Huang, Shiu-Feng Kathy
    Chang, Ming -Ling
    Liaw, Yun-Fan
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2024, 12 (02) : 218 - 221
  • [33] Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy
    Murata, Yasuhiro
    Hamada, Takashi
    Kishiwada, Masashi
    Ohsawa, Ichiro
    Mizuno, Shugo
    Usui, Masanobu
    Sakurai, Hiroyuki
    Tabata, Masami
    Ii, Noriko
    Inoue, Hiroyuki
    Shiraishi, Taizo
    Isaji, Shuji
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2012, 19 (04) : 413 - 425
  • [34] Preoperative radiotherapy with a simultaneous integrated boost compared to chemoradiotherapy for T3-4 rectal cancer: Interim analysis of a multicentric randomized trial
    Engels, B.
    De Paoli, A.
    Platteaux, N.
    Cattari, G.
    Vagge, S.
    Garibaldi, E.
    Norkus, D.
    Tabaro, G.
    Versmessen, H.
    De Ridder, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S481 - S481
  • [35] LAG-3-Expressing Tumor-Infiltrating T Cells Are Associated with Reduced Disease-Free Survival in Pancreatic Cancer
    Seifert, Lena
    Plesca, Ioana
    Mueller, Luise
    Sommer, Ulrich
    Heiduk, Max
    von Renesse, Janusz
    Digomann, David
    Gluck, Jessica
    Klimova, Anna
    Weitz, Juergen
    Schmitz, Marc
    Seifert, Adrian M.
    CANCERS, 2021, 13 (06) : 1 - 12
  • [36] Short-term results of laparoscopic surgery after preoperative chemoradiation for clinically staged T3 and T4 rectal cancer
    Hotchi, Masanori
    Shimada, Mitsuo
    Kurita, Nobuhiro
    Iwata, Takashi
    Sato, Hirohiko
    Morimoto, Shinya
    Yoshikawa, Kozo
    Higashijima, Jun
    Miyatani, Tomohiko
    Mikami, Chie
    Kashihara, Hideya
    ASIAN JOURNAL OF ENDOSCOPIC SURGERY, 2012, 5 (04) : 157 - 163
  • [37] Comparison between preoperative chemoradiotherapy and lateral pelvic lymph node dissection in clinical T3 low rectal cancer without enlarged lateral lymph nodes
    Tsukada, Yuichiro
    Rullier, Eric
    Shiraishi, Takuya
    Capdepont, Maylis
    Sasaki, Takeshi
    Celerier, Bertrand
    Denost, Quentin
    Ito, Masaaki
    COLORECTAL DISEASE, 2023, 25 (06) : 1153 - 1162
  • [38] The timing of surgery after preoperative short-course S-1 chemoradiotherapy with delayed surgery for T3 lower rectal cancer
    Naohito Beppu
    Nagahide Matsubara
    Masashi Noda
    Tomoki Yamano
    Hiroshi Doi
    Norihiko Kamikonya
    Naoki Yamanaka
    Hidenori Yanagi
    Naohiro Tomita
    International Journal of Colorectal Disease, 2014, 29 : 1459 - 1466
  • [39] The timing of surgery after preoperative short-course S-1 chemoradiotherapy with delayed surgery for T3 lower rectal cancer
    Beppu, Naohito
    Matsubara, Nagahide
    Noda, Masashi
    Yamano, Tomoki
    Doi, Hiroshi
    Kamikonya, Norihiko
    Yamanaka, Naoki
    Yanagi, Hidenori
    Tomita, Naohiro
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2014, 29 (12) : 1459 - 1466
  • [40] An analysis of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer on survival in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question?
    Bonnetain, F.
    Bosset, J.
    Gerard, J.
    Calais, G.
    Conroy, T.
    Mineur, L.
    Bouche, O.
    Maingon, P.
    Chapet, O.
    Radosevic-Jelic, L.
    Methy, N.
    Collette, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)